Laboratorios Farmacéuticos Rovi SA

Laboratorios Farmacéuticos Rovi SA is a Spanish biotechnology and pharmaceutical company specializing in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. Founded in 1946, it operates through two primary segments: Manufacturing, focused on contract development and manufacturing organization (CDMO) services with high-capacity facilities for pre-filled syringes and oral solids, and Marketing, which promotes a diversified portfolio of innovative patented products in Spain via specialized sales to physicians, hospitals, and pharmacies. A cornerstone of its offerings is low molecular weight heparin (HBPM), its flagship product distributed in over 60 countries through strategic international partnerships. The company emphasizes expanding heparin applications for chronic treatments and has recently expanded globally by acquiring an injectable manufacturing site in Phoenix, Arizona, enhancing its U.S. presence and rebranding its CDMO as ROIS. As a member of the IBEX 35 index, Laboratorios Farmacéuticos Rovi SA plays a significant role in the healthcare sector, particularly in drug manufacturing for specialty and generic pharmaceuticals, with 2,188 employees supporting its operations.